Global Biologics and Biosimilars 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI03255447

Publication Date:

March 25, 2025

Pages:

137

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Biologics and Biosimilars market size is predicted to grow from US$ 465450 million in 2025 to US$ 780800 million in 2031; it is expected to grow at a CAGR of 9.0% from 2025 to 2031.
Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products.
A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product"s patent expires. Reference to the innovator product is an integral component of the approval.
Global key biologics and biosimilars manufacturers include Johnson & Johnson, Pfizer, Roche, Amgen, AbbVie, and others. The top five manufacturers together account for approximately 50% of the market share, with the largest manufacturer being Pfizer with over 20% share. In terms of product categories, monoclonal antibodies are the largest segment with a market share of 43%, followed by vaccines with a 30% share. In terms of applications, hospitals are the top application area, with about 85% of the market share.
The 鈥淏iologics and Biosimilars Industry Forecast鈥� looks at past sales and reviews total world Biologics and Biosimilars sales in 2024, providing a comprehensive analysis by region and market sector of projected Biologics and Biosimilars sales for 2025 through 2031. With Biologics and Biosimilars sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biologics and Biosimilars industry.
This Insight Report provides a comprehensive analysis of the global Biologics and Biosimilars landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Biologics and Biosimilars portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Biologics and Biosimilars market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biologics and Biosimilars and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biologics and Biosimilars.
This report presents a comprehensive overview, market shares, and growth opportunities of Biologics and Biosimilars market by product type, application, key players and key regions and countries.
Segmentation by Type:
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others
Segmentation by Application:
Hospital
Retail Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Changchun High Tech
Kanghong Pharma
Innovent Biologics
Gan&Lee
Tonghua Dongbao
United Laboratory

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Biologics and Biosimilars 麻豆原创 Size (2020-2031)
2.1.2 Biologics and Biosimilars 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Biologics and Biosimilars by Country/Region (2020, 2024 & 2031)
2.2 Biologics and Biosimilars Segment by Type
2.2.1 Monoclonal Antibodies
2.2.2 Interferon
2.2.3 Insulin
2.2.4 Vaccines
2.2.5 Others
2.3 Biologics and Biosimilars 麻豆原创 Size by Type
2.3.1 Biologics and Biosimilars 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Biologics and Biosimilars 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Biologics and Biosimilars Segment by Application
2.4.1 Hospital
2.4.2 Retail Pharmacy
2.4.3 Other
2.5 Biologics and Biosimilars 麻豆原创 Size by Application
2.5.1 Biologics and Biosimilars 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Biologics and Biosimilars 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Biologics and Biosimilars 麻豆原创 Size by Player
3.1 Biologics and Biosimilars 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Biologics and Biosimilars Revenue by Player (2020-2025)
3.1.2 Global Biologics and Biosimilars Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Biologics and Biosimilars Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Biologics and Biosimilars by Region
4.1 Biologics and Biosimilars 麻豆原创 Size by Region (2020-2025)
4.2 Global Biologics and Biosimilars Annual Revenue by Country/Region (2020-2025)
4.3 Americas Biologics and Biosimilars 麻豆原创 Size Growth (2020-2025)
4.4 APAC Biologics and Biosimilars 麻豆原创 Size Growth (2020-2025)
4.5 Europe Biologics and Biosimilars 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Biologics and Biosimilars 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Biologics and Biosimilars 麻豆原创 Size by Country (2020-2025)
5.2 Americas Biologics and Biosimilars 麻豆原创 Size by Type (2020-2025)
5.3 Americas Biologics and Biosimilars 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Biologics and Biosimilars 麻豆原创 Size by Region (2020-2025)
6.2 APAC Biologics and Biosimilars 麻豆原创 Size by Type (2020-2025)
6.3 APAC Biologics and Biosimilars 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Biologics and Biosimilars 麻豆原创 Size by Country (2020-2025)
7.2 Europe Biologics and Biosimilars 麻豆原创 Size by Type (2020-2025)
7.3 Europe Biologics and Biosimilars 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Biologics and Biosimilars by Region (2020-2025)
8.2 Middle East & Africa Biologics and Biosimilars 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Biologics and Biosimilars 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Biologics and Biosimilars 麻豆原创 Forecast
10.1 Global Biologics and Biosimilars Forecast by Region (2026-2031)
10.1.1 Global Biologics and Biosimilars Forecast by Region (2026-2031)
10.1.2 Americas Biologics and Biosimilars Forecast
10.1.3 APAC Biologics and Biosimilars Forecast
10.1.4 Europe Biologics and Biosimilars Forecast
10.1.5 Middle East & Africa Biologics and Biosimilars Forecast
10.2 Americas Biologics and Biosimilars Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Biologics and Biosimilars Forecast
10.2.2 Canada 麻豆原创 Biologics and Biosimilars Forecast
10.2.3 Mexico 麻豆原创 Biologics and Biosimilars Forecast
10.2.4 Brazil 麻豆原创 Biologics and Biosimilars Forecast
10.3 APAC Biologics and Biosimilars Forecast by Region (2026-2031)
10.3.1 China Biologics and Biosimilars 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Biologics and Biosimilars Forecast
10.3.3 Korea 麻豆原创 Biologics and Biosimilars Forecast
10.3.4 Southeast Asia 麻豆原创 Biologics and Biosimilars Forecast
10.3.5 India 麻豆原创 Biologics and Biosimilars Forecast
10.3.6 Australia 麻豆原创 Biologics and Biosimilars Forecast
10.4 Europe Biologics and Biosimilars Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Biologics and Biosimilars Forecast
10.4.2 France 麻豆原创 Biologics and Biosimilars Forecast
10.4.3 UK 麻豆原创 Biologics and Biosimilars Forecast
10.4.4 Italy 麻豆原创 Biologics and Biosimilars Forecast
10.4.5 Russia 麻豆原创 Biologics and Biosimilars Forecast
10.5 Middle East & Africa Biologics and Biosimilars Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Biologics and Biosimilars Forecast
10.5.2 South Africa 麻豆原创 Biologics and Biosimilars Forecast
10.5.3 Israel 麻豆原创 Biologics and Biosimilars Forecast
10.5.4 Turkey 麻豆原创 Biologics and Biosimilars Forecast
10.6 Global Biologics and Biosimilars Forecast by Type (2026-2031)
10.7 Global Biologics and Biosimilars Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Biologics and Biosimilars Forecast
11 Key Players Analysis
11.1 Roche
11.1.1 Roche Company Information
11.1.2 Roche Biologics and Biosimilars Product Offered
11.1.3 Roche Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Roche Main Business Overview
11.1.5 Roche Latest Developments
11.2 Amgen
11.2.1 Amgen Company Information
11.2.2 Amgen Biologics and Biosimilars Product Offered
11.2.3 Amgen Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Amgen Main Business Overview
11.2.5 Amgen Latest Developments
11.3 AbbVie
11.3.1 AbbVie Company Information
11.3.2 AbbVie Biologics and Biosimilars Product Offered
11.3.3 AbbVie Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 AbbVie Main Business Overview
11.3.5 AbbVie Latest Developments
11.4 Sanofi
11.4.1 Sanofi Company Information
11.4.2 Sanofi Biologics and Biosimilars Product Offered
11.4.3 Sanofi Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Sanofi Main Business Overview
11.4.5 Sanofi Latest Developments
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Information
11.5.2 Johnson & Johnson Biologics and Biosimilars Product Offered
11.5.3 Johnson & Johnson Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Johnson & Johnson Main Business Overview
11.5.5 Johnson & Johnson Latest Developments
11.6 Pfizer
11.6.1 Pfizer Company Information
11.6.2 Pfizer Biologics and Biosimilars Product Offered
11.6.3 Pfizer Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Pfizer Main Business Overview
11.6.5 Pfizer Latest Developments
11.7 Novo Nordisk
11.7.1 Novo Nordisk Company Information
11.7.2 Novo Nordisk Biologics and Biosimilars Product Offered
11.7.3 Novo Nordisk Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Novo Nordisk Main Business Overview
11.7.5 Novo Nordisk Latest Developments
11.8 Eli Lilly
11.8.1 Eli Lilly Company Information
11.8.2 Eli Lilly Biologics and Biosimilars Product Offered
11.8.3 Eli Lilly Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Eli Lilly Main Business Overview
11.8.5 Eli Lilly Latest Developments
11.9 Novartis
11.9.1 Novartis Company Information
11.9.2 Novartis Biologics and Biosimilars Product Offered
11.9.3 Novartis Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Novartis Main Business Overview
11.9.5 Novartis Latest Developments
11.10 Merck
11.10.1 Merck Company Information
11.10.2 Merck Biologics and Biosimilars Product Offered
11.10.3 Merck Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Merck Main Business Overview
11.10.5 Merck Latest Developments
11.11 Biogen
11.11.1 Biogen Company Information
11.11.2 Biogen Biologics and Biosimilars Product Offered
11.11.3 Biogen Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Biogen Main Business Overview
11.11.5 Biogen Latest Developments
11.12 Celltrion
11.12.1 Celltrion Company Information
11.12.2 Celltrion Biologics and Biosimilars Product Offered
11.12.3 Celltrion Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Celltrion Main Business Overview
11.12.5 Celltrion Latest Developments
11.13 Sobi
11.13.1 Sobi Company Information
11.13.2 Sobi Biologics and Biosimilars Product Offered
11.13.3 Sobi Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Sobi Main Business Overview
11.13.5 Sobi Latest Developments
11.14 3SBIO
11.14.1 3SBIO Company Information
11.14.2 3SBIO Biologics and Biosimilars Product Offered
11.14.3 3SBIO Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 3SBIO Main Business Overview
11.14.5 3SBIO Latest Developments
11.15 Changchun High Tech
11.15.1 Changchun High Tech Company Information
11.15.2 Changchun High Tech Biologics and Biosimilars Product Offered
11.15.3 Changchun High Tech Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 Changchun High Tech Main Business Overview
11.15.5 Changchun High Tech Latest Developments
11.16 Kanghong Pharma
11.16.1 Kanghong Pharma Company Information
11.16.2 Kanghong Pharma Biologics and Biosimilars Product Offered
11.16.3 Kanghong Pharma Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.16.4 Kanghong Pharma Main Business Overview
11.16.5 Kanghong Pharma Latest Developments
11.17 Innovent Biologics
11.17.1 Innovent Biologics Company Information
11.17.2 Innovent Biologics Biologics and Biosimilars Product Offered
11.17.3 Innovent Biologics Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.17.4 Innovent Biologics Main Business Overview
11.17.5 Innovent Biologics Latest Developments
11.18 Gan&Lee
11.18.1 Gan&Lee Company Information
11.18.2 Gan&Lee Biologics and Biosimilars Product Offered
11.18.3 Gan&Lee Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.18.4 Gan&Lee Main Business Overview
11.18.5 Gan&Lee Latest Developments
11.19 Tonghua Dongbao
11.19.1 Tonghua Dongbao Company Information
11.19.2 Tonghua Dongbao Biologics and Biosimilars Product Offered
11.19.3 Tonghua Dongbao Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.19.4 Tonghua Dongbao Main Business Overview
11.19.5 Tonghua Dongbao Latest Developments
11.20 United Laboratory
11.20.1 United Laboratory Company Information
11.20.2 United Laboratory Biologics and Biosimilars Product Offered
11.20.3 United Laboratory Biologics and Biosimilars Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.20.4 United Laboratory Main Business Overview
11.20.5 United Laboratory Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.